Cingulate Inc.

What they do

Cingulate develops next-generation oral products built on its proprietary Precision Timed Release (PTR) platform, which incorporates an Erosion Barrier Layer designed to release drug at pre-defined intervals and enable once-daily, multi-dose tablets. Its lead candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both first-line stimulants targeting ADHD in children, adolescents and adults, plus CTx-2103 (buspirone) for anxiety. The company has no approved products and no product revenue; it funds operations through equity and debt financings while completing chemistry, manufacturing and controls (CMC) work and commercial launch preparations.

Revenue drivers

• CTx-1301 (dexmethylphenidate, ADHD) — Lead asset and the primary potential future revenue source; the company cites an ADHD stimulant market of roughly 100 million annual US prescriptions and an average branded long-acting stimulant WAC of $495/Rx, and states that a 1% share could represent approximately $250-$300 million in annual revenue less rebates and discounts. It is pre-approval and generated no revenue.
• CTx-1302 (dextroamphetamine, ADHD) — Second PTR-based stimulant candidate for the same ADHD patient segments; no revenue and no disclosed approval timeline in the excerpts.
• CTx-2103 (buspirone, anxiety) — Earlier-stage program for once-daily buspirone; the company cites 2025 US buspirone sales of over $1 billion within a $15.2 billion anxiety and depression market and an average 2.3 daily buspirone doses per patient.

Recent performance

Cingulate reported a second-quarter 2026 8-K earnings release on August 13, 2026, disclosing cash and cash equivalents of $28.4 million at June 30, 2026 versus $11.0 million at December 31, 2025. The company attributes the increase to a $12.0 million private placement closed in the first quarter plus $19.0 million raised under its At-the-Market agreement with AGP and purchase agreement with Lincoln Park Capital, partially offset by $12.8 million of cash used in operations. It reported no product revenue, consistent with being pre-commercial. Reported net losses were $16.6 million in 2024 and $22.4 million in 2025, with operating cash use of $18.5 million and $17.2 million, respectively. Total assets were $33.1 million and total liabilities $9.6 million at June 30, 2026, leaving shareholder equity of $23.5 million.

Strategy

Management's stated priorities are to complete remaining manufacturing work, submit a comprehensive response to the FDA and continue preparing for commercialization. CTx-1301's NDA resubmission follows a Complete Response Letter issued June 1, 2026, which requested additional CMC information and did not identify concerns regarding clinical safety or efficacy. CMC and process validation are being conducted with contract developer and manufacturer Bend Bioscience. Commercial readiness work includes an exclusive distribution services agreement signed July 21, 2026 with Prasco, LLC covering major wholesalers and roughly 19,000 independent and smaller regional pharmacies, a master services agreement with Indegene for market access and marketing, and field deployment planning with IQVIA. The company also received US Patent No. 12,653,791 on June 16, 2026 covering CTx-1301 through December 2042.

Risks

• No approved product or revenue — CTx-1301 has not received FDA approval, and the June 1, 2026 Complete Response Letter requires additional CMC information before the NDA can be resubmitted.
• Capital needs and going-concern risk — The company discloses a history of operating losses, expects substantial future costs, and states that failure to raise additional capital could require bankruptcy protection or alternatives that would likely cause securityholders to lose some or all of their investment.
• Restrictive debt covenants — The Note Purchase Agreement and note issued in November 2025 contain restrictive covenants and default adjustments that may limit operating flexibility and affect business operations and financial condition.
• Nasdaq listing compliance — Maintaining compliance with Nasdaq continued listing requirements is identified in both the 10-K and 10-Q forward-looking statement lists, and the company's diluted EPS history includes a 2023 loss of $311.99 per share.

Outlook

Management says it plans to resubmit the CTx-1301 NDA to the FDA as promptly as practicable after completing the requested CMC work with its manufacturing partner. The $28.4 million in cash at June 30, 2026 is described as providing runway through mid-2027, and the company states it is advancing market access, payer readiness and manufacturing ahead of a potential launch.